Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/269 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME11350488
PMID: | 11350488
LR: | 20061115
CED: | 20010514
DCO: | 20010607
Autoren: | Weimann G; Lubenow N; Selleng K; Eichler P; Albrecht D; Greinacher A
Titel: | Glucosamine sulfate does not crossreact with the antibodies of patients with heparin-induced thrombocytopenia.
Quelle: | European journal of haematology; VOL: 66 (3); p. 195-9 /200103/
PM: | Print
SU: | IM
Sprache: | English
CY: | Denmark
JID: | 8703985
ISSN: | 0902-4441
CO: | EJHAEC
Institution: | Institut für Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt-University Greifswald, Sauerbruchstr/Diagnostikzentrum, 17487 Greifswald, Germany.
DT: | Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
Schlagwörter
CT: | ANTIBODY SPECIFICITY; AUTOANTIBODIES/*immunology; AUTOIMMUNE DISEASES/*chemically induced; AUTOIMMUNE DISEASES/immunology; BLOOD PLATELETS/drug effects; BLOOD PLATELETS/secretion; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOSAMINE/*immunology; GLYCOSAMINOGLYCANS/chemistry; GLYCOSAMINOGLYCANS/immunology; HEPARIN/*adverse effects; HUMANS; OSTEOARTHRITIS/drug therapy; PLATELET ACTIVATION/drug effects; PLATELET FACTOR 4/metabolism; SEROTONIN/secretion; THROMBOCYTOPENIA/*chemically induced; THROMBOCYTOPENIA/immunology
CTG: | ANTIKÖRPERSPEZIFITÄT; AUTOANTIKÖRPER/*Immunologie; AUTOIMMUNKRANKHEITEN/*chemisch hervorgerufen; AUTOIMMUNKRANKHEITEN/Immunologie; THROMBOZYTEN/Arzneimittelwirkungen; THROMBOZYTEN/Sekretion; KREUZREAKTIONEN; ENZYMIMMUNTEST (ELISA); GLUCOSAMIN/*Immunologie; GLYCOSAMINO-GLYCANE/Chemie; GLYCOSAMINO-GLYCANE/Immunologie; HEPARIN/*unerwünschte Nebenwirkungen; MENSCH; OSTEOARTHROSE/Arzneimitteltherapie; THROMBOZYTENAKTIVIERUNG/Arzneimittelwirkungen; THROMBOZYTEN-FAKTOR IV/Stoffwechsel; SEROTONIN/Sekretion; THROMBOZYTOPENIE/*chemisch hervorgerufen; THROMBOZYTOPENIE/Immunologie
TE: | Autoantibodies; Glycosaminoglycans; Glucosamine/3416-24-8; Platelet Factor 4/37270-94-3; Serotonin/50-67-9; Heparin/9005-49-6
CR: | 3416-24-8; 37270-94-3; 50-67-9; 9005-49-6
AB: | OBJECTIVE: To assess the crossreactivity of glucosamine sulfate, used for treatment of degenerative joint disease with antibodies induced in heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a severe adverse effect of heparin therapy induced by an immunological mechanism. The antibodies in HIT are induced by a complex of heparin and, in most cases, platelet factor 4. Hereby generation of the antigen is not strictly dependent on heparin. Heparin can be substituted by a variety of polysulfated carbohydrates. In vitro and in vivo crossreactivity of HIT antibodies has been demonstrated for a chemically polysulfated chondroitin-like substance (Arteparon, Luitpoldwerke, Munich, Germany), formerly used for chondroprotection. Another drug widely used in the treatment of degenerative joint disease is glucosamine sulfate. Glucosamine is a building block of glycosaminoglycans, of which heparin is the clinically most important. Many patients with degenerative joint disease use glucosamine sulfate. This group is also at the highest risk to develop HIT following joint replacement surgery. METHODS: We examined the interactions of glucosamine sulfate (DONA 200-S, Opfermann, Wiehl, Germany) with platelets and antibodies of patients with HIT in and without the presence of heparin. Sera of 5 HIT patients and platelets of 4 healthy donors were used. The binding of HIT antibodies to PF4/glucosamine sulfate complexes was assessed by an ELISA. RESULTS: HIT antibodies did not activate platelets in the presence of glucosamine sulfate in a serotonin-release assay. Preincubation with glucosamine sulfate did not inhibit platelet activation by HIT antibodies in the presence of heparin (0.2 IU/ml). Antibodies bonded to PF4/heparin but not to PF4/glucosamine sulfate complexes. CONCLUSIONS: In contrast to sulfated glycosaminoglycans, there is no evidence for an immunological crossreactivity of HIT antibodies between heparin and glucosamine sulfate.

» Volltext »
» Fenster schließen »